Through meta‐analysis for combining cox results of three data sets, it demonstrated that SLC12A5 could be used as an independent prognostic factor for overall survival in glioma patients (HR = 0.53, p < 0.001) (Figure 3B). This evidence concerns the gene SLC12A5 and central nervous system cancer.